Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBITDA (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EBITDA data on record, last reported at -$58.8 million in Q4 2025.

  • For Q4 2025, EBITDA fell 54.2% year-over-year to -$58.8 million; the TTM value through Dec 2025 reached -$215.3 million, up 8.8%, while the annual FY2025 figure was -$215.3 million, 8.64% up from the prior year.
  • EBITDA reached -$58.8 million in Q4 2025 per MRVI's latest filing, down from -$41.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $180.7 million in Q2 2022 and bottomed at -$165.6 million in Q3 2024.
  • Average EBITDA over 5 years is $32.3 million, with a median of -$9.4 million recorded in 2023.
  • Peak YoY movement for EBITDA: soared 1799.57% in 2021, then plummeted 974.23% in 2024.
  • A 5-year view of EBITDA shows it stood at $151.1 million in 2021, then fell by 27.69% to $109.2 million in 2022, then tumbled by 106.54% to -$7.2 million in 2023, then plummeted by 433.29% to -$38.1 million in 2024, then tumbled by 54.2% to -$58.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$58.8 million in Q4 2025, -$41.0 million in Q3 2025, and -$66.3 million in Q2 2025.